Physician profile
Hammad Shafqat
NPI 1093070302
$1,501.42
in general payments reported to CMS, 2019-2025
21 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $110 · 2021: $48.67 · 2022: $451 · 2023: $213 · 2024: $475 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.85 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $278.70 | 2020-2025 | |
| Abbvie INC. | $231.66 | 2022-2024 | Venclexta |
| Incyte Corporation | $139.98 | 2022-2023 | Monjuvi, Pemazyre, Jakafi |
| Pfizer INC. | $130.60 | 2022-2025 | |
| Tempus Ai, INC | $121.52 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $112.68 | 2019-2024 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $85.48 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Adaptive Biotechnologies Corporation | $77.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $73.03 | 2023-2024 | Libtayo |
| Seagen INC. | $44.26 | 2023 | Tukysa |
| Eisai INC. | $36.98 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $21.02 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.92 | 2025 | Monoferric |
| Immunocore Limited | $20.03 | 2024 | Kimmtrak |
| Merck Sharp & Dohme LLC | $18.51 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.65 | 2022 | |
| Genzyme Corporation | $15.20 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.84 | 2022 | |
| Gilead Sciences, INC. | $14.30 | 2024 | |
| Stemline Therapeutics INC. | $13.43 | 2023 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Shafqat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.